SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluidigm Corporation today announced the pricing of its initial public offering of 5,558,333 shares of its common stock at a price to the public of $13.50 per share. The shares of common stock have been approved to trade on The NASDAQ Global Market under the symbol “FLDM.”
Deutsche Bank Securities Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cowen and Company LLC and Leerink Swann acted as co-managers. Fluidigm has granted the underwriters an option to purchase up to an additional 833,750 shares of common stock to cover over-allotments, if any.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 9, 2011.
This offering is being made solely by means of a prospectus, copies of which may be obtained from: Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, or by calling (800) 503-4611 or emailing a request to email@example.com or by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by calling 1-800-747-3924.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories and Ag-Bio companies.
For more information, please visit www.fluidigm.com
“Fluidigm” and the Fluidigm logo are trademarks or registered trademarks of Fluidigm.
Howard High, 650-266-6081 (office)